Neurodevelopmental Disorders, Maternal Rh-Negativity, and Rho(D) Immune Globulins: A Multi-Center Assessment

David A. Geier¹, Elizabeth Mumper², Bambi Gladfelter², Lisa Coleman², and Mark R. Geier³

1. The Institute of Chronic Illnesses, Inc., Silver Spring, MD 20905; 2. Advocates for Children Pediatrics, Ltd., Lynchburg, VA 24501; USA. 3. The Genetic Centers of America

Correspondence to: Mark R. Geier, 14 Redgate Ct. Silver Spring, MD 20905, USA. PHONE: (301)989-0548; FAX: (301)989-1543 EMAIL: mgeier@comcast.net

Submitted: 2007-12-19 Accepted: 2008-02-12 Published online: 2008-04-18

Key words: developmental delay; ethylmercury; merthiolate; rhogam; thiomersal

Abstract

BACKGROUND: Many formulations of Thimerosal (49.55% mercury by weight)-containing Rho(D) immune globulins (TCRs) were routinely administered to Rh-negative mothers in the US prior to 2002.

OBJECTIVES: It was hypothesized: (1) if prenatal Rho(D)-immune globulin preparation exposure was a risk factor for neurodevelopmental disorders (NDs) then more children with NDs would have Rh-negative mothers compared to controls; and (2) if Thimerosal in the Rho(D)-immune globulin preparations was the ingredient associated with NDs, following the removal of Thimerosal from all manufactured Rho(D)-immune globulin preparations from 2002 in the US the frequency of maternal Rh-negativity among children with NDs should be similar to control populations.

METHODS: Maternal Rh-negativity was assessed at two sites (Clinic A-Lynchburg, VA; Clinic B-Rockville and Baltimore, MD) among 298 Caucasian children with NDs and known Rh-status. As controls, maternal Rh-negativity frequency was determined from 124 Caucasian children (born 1987–2001) without NDs at Clinic A, and the Rh-negativity frequency was determined from 1,021 Caucasian pregnant mothers that presented for prenatal genetic care at Clinic B (1980–1989). Additionally, 22 Caucasian patients with NDs born post-2001 (Clinics A and B) were assessed for maternal Rh-negativity.

RESULTS: There were significant and comparable increases in maternal Rh-negativity among children with NDs (Clinic: A=24.2%, autism spectrum disorders (Clinic: A=28.3%, B=25.3%), and attention-deficit-disorder/attention-deficit-hyperactivity-disorder (Clinic: A=26.3%) observed at both clinics in comparison to both control groups (Clinic: A=12.1%, B=13.9%) employed. Children with NDs born post-2001 had a maternal Rh-negativity frequency (13.6%) similar to controls.

CONCLUSION: This study associates TCR exposure with some NDs in children.

Potential Conflict of Interest: David Geier has been a consultant in legal cases involving vaccines/biologics. Dr. Elizabeth Mumper and Dr. Mark Geier have been expert witnesses and consultants in legal cases involving vaccines/biologics.